These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 28035989)

  • 41. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
    Carlsen NL
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer.
    Wulf AM; Moreno MM; Paka C; Rampasekova A; Liu KJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroblastoma.
    Castleberry RP
    Eur J Cancer; 1997 Aug; 33(9):1430-7; discussion 1437-8. PubMed ID: 9337686
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting RAS in neuroblastoma: Is it possible?
    Lin L; Miao L; Lin H; Cheng J; Li M; Zhuo Z; He J
    Pharmacol Ther; 2022 Aug; 236():108054. PubMed ID: 34915055
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genome and transcriptome analysis of neuroblastoma advanced diagnosis from innovative therapies.
    Coco S; Tonini GP; Stigliani S; Scaruffi P
    Curr Pharm Des; 2009; 15(4):448-55. PubMed ID: 19199972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview of current treatment of neuroblastoma.
    Philip T
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):97-102. PubMed ID: 1382390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
    Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
    BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroblastoma: molecular pathogenesis and therapy.
    Louis CU; Shohet JM
    Annu Rev Med; 2015; 66():49-63. PubMed ID: 25386934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cancer evolution, mutations, and clonal selection in relapse neuroblastoma.
    Schulte M; Köster J; Rahmann S; Schramm A
    Cell Tissue Res; 2018 May; 372(2):263-268. PubMed ID: 29478075
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
    Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
    J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; Caron HN; van Dalen EC
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Origin and initiation mechanisms of neuroblastoma.
    Tsubota S; Kadomatsu K
    Cell Tissue Res; 2018 May; 372(2):211-221. PubMed ID: 29445860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Oncogenic factors of metastatic dissemination in neuroblastoma].
    Da Silva J; Duarte N; Cappellen D; Bettan-Renaud L; Dubourg C; Ferrandis E; Guigay J; Schrodt S; McDowell H; Barrois M; Ahomadegbe JC; Terrier-Lacombe MJ; Bourhis J; Hartmann O; Benard J
    C R Seances Soc Biol Fil; 1998; 192(2):261-71. PubMed ID: 9759369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.
    Cornero A; Acquaviva M; Fardin P; Versteeg R; Schramm A; Eva A; Bosco MC; Blengio F; Barzaghi S; Varesio L
    BMC Bioinformatics; 2012 Mar; 13 Suppl 4(Suppl 4):S13. PubMed ID: 22536959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroblastoma: When differentiation goes awry.
    Zeineldin M; Patel AG; Dyer MA
    Neuron; 2022 Sep; 110(18):2916-2928. PubMed ID: 35985323
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.
    Kholodenko IV; Kalinovsky DV; Doronin II; Deyev SM; Kholodenko RV
    J Immunol Res; 2018; 2018():7394268. PubMed ID: 30116755
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
    Yalçin B; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mouse models of high-risk neuroblastoma.
    Kamili A; Atkinson C; Trahair TN; Fletcher JI
    Cancer Metastasis Rev; 2020 Mar; 39(1):261-274. PubMed ID: 31989509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spontaneous regression of neuroblastoma.
    Brodeur GM
    Cell Tissue Res; 2018 May; 372(2):277-286. PubMed ID: 29305654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.